Part 4/12:
What distinguishes this drug from previous treatments is its ability to affect the root cause rather than just manage symptoms temporarily. Remarkably, the drug slowed disease progression by 27% over an 18-month trial—equivalent to providing patients with an additional six months of healthier life. This marks a potential turning point, offering a glimpse into a future where the course of Alzheimer’s might be modified or even prevented.